Abstract: A method, system, and computer-readable media for providing a mountable directed-energy system comprising a directed-energy source for generating and transmitting directed-energy. At least a portion of the directed-energy system may be mounted to one or more other devices such as any of a vehicle, drone, or other manually operated, autonomous, or semi-autonomous system.

Abstract: The present invention provides improved methods for gene delivery to, or genetic modification of, target cells, wherein the gene delivery or other genetic modification of the target cells is performed in the presence of endothelial cells, or after co-culture of the target cells with endothelial cells, or wherein co-culture of the target cells with endothelial cells is employed immediately after gene delivery in order to “rescue” cells that may have been damaged during the gene delivery process. In some embodiments gene delivery is performed by transfection. In some embodiments gene delivery is performed by transduction. In some embodiments the endothelial cells are organ-specific endothelial cells. In some embodiments the endothelial cells are E4ORF1-expressing endothelial cells (E4ORF1+ ECs). In some embodiments the target cells are stem cells, such as hematopoietic stem cells.

Abstract: A laser weapon system is described. Particularly, embodiments describe subsystems of a laser weapon system including those necessary for laser generation, operational control, optical emission, and heat dissipation configured to provide a lightweight unit of reduced dimensions.

Abstract: The present disclosure relates to the field of hematopoietic stem or progenitor cell transplantation. More specifically, methods, compositions and kits for improving expansion and engraftment of hematopoietic stem or progenitor cells by co-culturing and co-administering with endothelial cells are provided. The methods, compositions and kits are useful for treating various disorders relating to deficiencies in hematopoiesis caused by disease or myeloablative treatments.

Abstract: The present invention relates, in part, to blood-brain barrier-like tissues that comprise engineered E40RF1+ endothelial cells, and to various compositions and methods useful for making and using such blood-brain barrier-like tissues—both in vitro and in vivo.

Abstract: A laser weapon system is described. Particularly, embodiments describe subsystems of a laser weapon system including those necessary for laser generation, operational control, optical emission, and heat dissipation configured to provide a lightweight unit of reduced dimensions.

Abstract: A laser weapon system is described. Particularly, embodiments describe subsystems of a laser weapon system including those necessary for laser generation, operational control, optical emission, and heat dissipation configured to provide a lightweight unit of reduced dimensions.

Abstract: A laser weapon system is described. Particularly, embodiments describe subsystems of a laser weapon system including those necessary for laser generation, operational control, optical emission, and heat dissipation configured to provide a lightweight unit of reduced dimensions.

Abstract: A multi-stage computing framework may allow development, in an unrestricted computing region, of one or more computing resources that are transferred to, and deployed in, a restricted computing region. The computing framework may include a development module and a transfer module. The development module may allow development of the computing resources in the unrestricted computing region, for example including stages such as a resource creation, linting, scanning, validation, packaging and requesting of the transfer. The transfer module may allow management of the transfer of the computing resources from the unrestricted computing region to the restricted computing region, for example including stages such as control, transfer request queueing, performance of the transfer, transfer notification and transfer visualization.

Abstract: The present invention provides non-thymic endothelial cells (ntECs) engineered to express adenovirus E4ORF1 and/or BMP4, and compositions comprising such engineered ntECs. The present invention also provides methods of using such ntECs in therapy, for example to enhance thymic regeneration (including T cell reconstitution) in subjects in need thereof. Such subjects include those that have a damaged thymus, defective thymic function, insufficient T-cell output, and/or that are immunocompromised—for example as a result of ageing, infection (e.g. with HIV), treatment with radiation therapy, treatment with chemotherapy, or myeloablative conditioning in preparation for an organ/tissue transplant.

Abstract: In some aspects the present invention relates to engineered endothelial cells, such as E4ORF1+ ETV2+ engineered endothelial cells. In other aspects the present invention relates to methods of making such engineered endothelial cells, and methods of using such engineered endothelial cells, for example in co-culture applications.

Abstract: A laser weapon system is described. Particularly, embodiments describe subsystems of a laser weapon system including those necessary for laser generation, operational control, optical emission, and heat dissipation configured to provide a lightweight unit of reduced dimensions.

Abstract: The present invention relates, in part, to blood-brain barrier-like tissues that comprise engineered E40RF1+ endothelial cells, and to various compositions and methods useful for making and using such blood-brain barrier-like tissues—both in vitro and in vivo.

Abstract: A laser weapon system is described. Particularly, embodiments describe subsystems of a laser weapon system including those necessary for laser generation, operational control, optical emission, and heat dissipation configured to provide a lightweight unit of reduced dimensions.

Abstract: In some aspects the present invention relates to engineered endothelial cells, such as E40RF1+ ETV2+ engineered endothelial cells. In other aspects the present invention relates to methods of making such engineered endothelial cells, and methods of using such engineered endothelial cells, for example in co-culture applications.

Abstract: In certain aspects the present invention provides engineered neural cells, neural stem cells, or neural progenitor cells that contain a nucleotide sequence that encodes an adenovirus E40RF1 polypeptide and/or that contain an adenovirus E40RF1 polypeptide. The present invention also provides methods of making and using such engineered cells and compositions comprising such engineered cells.

Abstract: The present invention provides methods for treating spinal cord injury (SCI). Such methods involve administering E40RF1+ endothelial cells and neural cells (such as neural progenitor cells (NPCs), glial progenitor cells, or glial cells) to subjects having a SCI. The present invention also provides compositions useful in such methods, such as compositions comprising E40RF1+ endothelial cells and/or neural cells (such as NPCs, glial progenitor cells, or glial cells).

Abstract: A laser weapon system is described. Particularly, embodiments describe subsystems of a laser weapon system including those necessary for laser generation, operational control, optical emission, and heat dissipation configured to provide a lightweight unit of reduced dimensions.

Abstract: The present invention provides improved methods for gene delivery to, or genetic modification of target cells, wherein the gene delivery or other genetic modification of the target cells is performed in the presence of endothelial cells, or after co-culture of the target cells with endothelial cells, or wherein co-culture of the target cells with endothelial cells is employed immediately alter gene delivery in order to “rescue” cells that may have been damaged during the gene delivery process. In some embodiments gene delivery is performed by transfection. In some embodiments gene delivery is performed by transduction, in some embodiments the endothelial cells are organ-specific endothelial cells. In some embodiments the endothelial cells are E40RF1-expressing endothelial cells (E40RF1+ ECs). In some embodiments the target cells are stem cells, such as hematopoietic stem cells.